Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683239 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,331
- Enrollment target
NCT02683239 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 5,331 participants.
The verdict
NCT02683239, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,331 participants
- Enrollment target
Study Summary
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
Interventions
- DRUG Placebo
- DRUG Fasinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,331 participants |
| Start Date | 2016-02-17 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02683239
The ClinicalTrials.gov registry entry for NCT02683239 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02683239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02683239 about?
NCT02683239 is a clinical study titled "Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip". The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
What is the current status of trial NCT02683239?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,331 participants. The study started on 2016-02-17. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT02683239?
The interventions under investigation include: Placebo (DRUG), Fasinumab (DRUG).
Who is sponsoring clinical trial NCT02683239?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.